Fox Business - The Power to Prosper
Search Site

Forest Laboratories

Icahn Enterprises Reports Profit Up 144% In 2013

Icahn Enterprises L.P. earned a profit of $1.025 billion, or $9.07 per share in 2013, from revenue of $21 billion -- a 144% increase in profitability from a year ago, Carl Icahn announced in a letter to shareholders Monday. Icahn credited his success to the company's activist investing strategy, which he said eliminates "mediocre CEOs and wasteful bureaucracy." The company's investment segment saw large profits, including the sale of Forest Laboratories Inc. to Actavis PLC , which Icahn said netted the company gains of 209% over the original purchase price. The company's shares were trading at $111.60, up 0.3%, Monday morning.Copyright © 2014 MarketWatch, Inc....

Read More

  1. Forest Labs Ups Full-Year Profit Outlook

    Forest Laboratories Inc's results handily beat analysts' estimates in the first full quarter under new Chief Executive Brent Saunders, and the company raised its ful...

  2. Forest Labs Swallows Aptalis in $2.9B Buyout

    In a bid to diversify its offerings, drug maker Forest Laboratories (NYSE:FRX) unveiled an all-cash buyout on Wednesday of privately held rival Aptalis for $2.9 bill...

  3. Dow Slumps Ahead of FOMC Minutes

    FOX Business: Capitalism Lives HereThe blue-chip index dipped Wednesday as traders shrugged off upbeat data on the jobs market and braced for the latest minutes from...

  4. Economy Takes Center Stage, Street Dips

    FOX Business: Capitalism Lives HereThe broad S&P 500 edged lower, while the Dow took heavier losses, as traders digested upbeat economic data and Fed minutes. Today'...

  5. Forest Laboratories Acquires Aptalis For $2.9 Bln

    Forest Laboratories Inc. said Wednesday it would acquire the specialty pharmaceutical company Aptalis for $2.9 billion in cash from the investment firm TPG. Aptalis,...

  6. Futures Slip Despite Strong Employment Data

    FOX Business: Capitalism Lives HereU.S. stock-index futures fell slightly Wednesday despite significantly better-than-expected data on private-sector employment. Tod...

  7. Forest Labs Plans To Buy Schizophrenia Drug, Cut Costs

    Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it planned to buy rights to a new schizophrenia drug from...

  8. New CEO signals strategic changes at Forest Labs

    Forest Laboratories Inc's new chief executive signaled strategic changes that will help the drugmaker focus on multiple new growth areas as it prepares to lose paten...

  9. Perrigo to Buy Ireland's Elan

    U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatm...

  10. Exclusive: Forest interested in bidding for Irish drugmaker Elan - sources

    Forest Laboratories Inc is among a handful of companies interested in bidding for Irish drugmaker Elan Corp , according to two people familiar with the situation who...

  11. Forest Labs to add Icahn representative to board, avert proxy fight

    Forest Laboratories Inc said on Tuesday it will add a representative of Carl Icahn as an independent member to its board, averting a new proxy battle with the billio...

  12. DOJ subpoenas documents on Forest Labs' inhalation drug

    Drugmaker Forest Laboratories received a subpoena earlier this month from U.S. prosecutors requesting documents relating to its small-selling lung disorder product, ...

  1. Pharma ETFs On The Move Again (IHE, PJP, PPH, ACT, FRX)

    First it was the biotech stocks, now the large pharmaceuticals are getting in on the act.The two sectors have been attracting money all year and were barely phased b...

  2. Actavis, Forest Labs Join Forces in $25B Deal

    Irish drug maker Actavis (NYSE:ACT) launched a $25 billion cash-and-stock buyout of rival Forest Laboratories (NYSE:FRX) on Tuesday, forming a beefed-up specialty ph...

  3. Actavis to buy Forest Labs in $25 billion deal

    Generic drugmaker Actavis Plc said it would acquire specialty pharmaceuticals company Forest Laboratories Inc in a cash and stock deal it valued at about $25 billion...

  4. Stock Futures Pare Gains on Weak Data

    FOX Business: Capitalism Lives HereU.S. stock-index futures fell from session highs Tuesday after a regional manufacturing gauge came in well below expectations. Tod...

  5. Stocks Slip as Housing, Factory Data Disappoint

    FOX Business: Capitalism Lives HereU.S. equity markets slumped on Tuesday as traders reviewed concerning data on the American housing and factory sectors.Today's Mar...

  6. S&P Closes in on Record High

    FOX Business: Capitalism Lives HereAfter a choppy start to the year, the broad S&P 500 extended its climb toward record highs on Tuesday.Today's MarketsThe Dow Jones...

  7. Actavis Confirms $25 Bln Forest Labs Acquistion

    Actavis PLC confirmed early Tuesday it will buy Forest Laboratories Inc. in an equity-and-cash deal valuing the New York-based pharmaceutical firm at $25 billion. Un...

‹ Prev123Next ›
Freebase CC-BY
Source: Forest Laboratories on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL